Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CiVi Biopharma Appoints New CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

CiVi Biopharma Appoints New CEO

Mr. Jacobovitz comes with decades of experience

By: Betsy Louda

, Contract Pharma

CiVi Biopharma has appointed Shalom “Shal” Jacobovitz as chief executive officer and a director on their Board of Directors effective February 2, 2018.  

 

Mr. Jacobovitz most recently served as chief executive officer of the American College of Cardiology, and before that, as president of Actelion Pharmaceuticals.

 

“We are extremely pleased to welcome Shal to CiVi Biopharma,” said Aaron Davis, chief executive officer of Boxer Capital, and executive chairman of CiVi Biopharma.  “As CiVi prepares to dose the first patient in January 2018 in its phase I clinical trial for the Company’s lead product candidate, CiVi007, a long-acting PCSK9 inhibitor being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease, Shal’s vast knowledge of the treatment landscape for cardiovascular diseases will play a critical role in the Company’s future development plans.”

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters